Novo Nordisk is buying a Canadian pharmaceutical company that develops treatments for obesity and diabetes for just over $1 billion, the Danish pharmaceutical company said. announced on thursday.
Novo Nordisk, which already produces the popular weight-loss drugs Ozempic and Wegoby, has acquired Inversago Pharma for 10 days in hopes of investigating the potential of a major project to treat obesity and obesity-related complications. announced that it has agreed to acquire the company for $75 million.
Inversago’s INV-202 works by a different mechanism than Ozempic, Wegovy, and Eli Lilly’s Mounjaro, which is intended to treat diabetes and aid weight loss efforts by activating the GLP-1 receptor.
INV-202, on the other hand, works by blocking CB1 receptors involved in regelation of metabolism and appetite.
“The acquisition of Inversago Pharma will further strengthen our clinical development pipeline in obesity and related diseases,” said Martin Horst Lange, executive vice president of development at Novo Nordisk, in a statement on Thursday. Stated.
“This promising class of medicine pioneered by the Inversago team has the potential to lead to new, life-changing treatment options for people living with serious chronic diseases, especially those living with obesity. We may offer complementary solutions,” he added.
François Ravenel, CEO of Inversago, similarly suggested that the acquisition would help “to maximize the medical potential of our CB1 blockers.”
“We are pleased to partner with the world leader in obesity and metabolic diseases,” Ravenel said in a statement.
Copyright 2023 Nexstar Media Inc. All rights reserved. You may not publish, broadcast, rewrite or redistribute this material.
